France's ANSM orders French biotech Theravectys to suspend manufacturing

Another French biotech has had its clinical supply manufacturing shut down by French drug regulator ANSM, after inspectors found a number of serious problems. According to a recent report posted by the European Medicines Agency, ANSM inspectors in November took a look at Theravectys in Villejuif, France, a biotech which is producing lentiviral vectors for clinical development and doing cell work for chimeric antigen receptors (CARs) and T-cell receptor (TCR)-based cell therapies. The facility was only approved in April of last year. During the inspection, they found 45 deficiencies, 5 of which they deemed critical and 17 major. They included testing media fill with "unqualified equipment." Last year, regulators recommended the same action against TxCell, a French biotech working on T-cell treatments for chronic inflammatory and autoimmune diseases. TxCell has since transferred its manufacturing to a contractor. Access the EMA report here | More

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.